Jonas Bergquist

faculty.utah.edu

Jonas Bergquist, MD, PhD, is a Full Chair Professor in Analytical Chemistry and Neurochemistry at the Department of Chemistry at Uppsala University. He also has served as an Associate Professor of Clinical Neuroscience at the Sahlgrenska University Hospital and Gothenburg University, Gothenburg, Sweden. In 1999, he became a Researcher in Uppsala University, Uppsala, Sweden. In 2005, he was appointed the Chaired Professor of Analytical Chemistry and Neurochemistry, heading the Bergquist group at the Department of Chemistry, Biomedical Centre, Uppsala University. Since 2011, he is an Adjunct Professor of Pathology at the University of Utah, Salt Lake City, US, and since 2015, a Professor of Precision Medicine, Binzhou Medical University, Yantai, China.

Research interests: various neurodegenerative diseases such as Parkinson's, Alzheimer's, amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS); his research "involves methods to measure substances that can act as biomarkers for early diagnosis and contribute to the understanding of what initiates the disease process... [and] measure not only the individual substances but also seek patterns and monitor how they change during illness,... [the Bergquist group's] specialty is the analysis of cerebrospinal fluid and its chemical composition."

Dr Bergquist leads the Open Medicine Foundation's center in Uppsala, Sweden.

Long COVID

Professor Bergquist is principal investigator for the Open Medicine Foundation's COVID-19 and ME/CFS study, which was announced in May 2020.

Working groups and committees

ME/CFS Collaborative Research Center at Stanford University

Member of the Working Group which offers their expertise and resources to the ME/CFS Collaborative Research Center at Stanford University.

EUROMENE

Dr. Bergquist is a member of the Biomarkers Working Group of ME/CFS across Europe on behalf of the EUROMENE, a European Union COST Action CA15111 not-for-profit research organization committed to tackling the cause and treatment for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome.

ME/CFS Common Data Element (CDE) Project

Member of the Biomarkers Working Group and Neurologic/Cognitive/CNS Imaging Working Group of the Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Common Data Element (CDE) Project sponsored by the National Institute of Neurological Disorders and Stroke and the Centers for Disease Control and Prevention.

2017 Ramsay Award

A team comprised of Dr. Bergquist and Dr. Jonas Blomberg of Uppsala University and Dr. Carl-Gerhard Gottfries and Dr. Olof Zachrisson of the Gottfries Clinic were awarded a 2017 Ramsay Award grant from the Solve ME/CFS Initiative for research into biomarkers for initiation (infection) and metabolic derangement in ME/CFS.

Talks and interviews

• 2015, Speaker at the 10th Invest in ME International ME Conference - (no speech title given) DVD available
• 12 Aug 2017, Community Symposium on the Molecular Basis of ME/CFS - 2017: Speech title - In search of biomarkers revealing pathophysiology in a Swedish ME/CFS patient cohort

• 3-5 May 2018, ME/CFS Canadian Collaborative Team Conference - Speech title: The Biochemistry to Support the Evidence of Neuroinflammatory Involvement in ME/CFS
• 29 Sep 2018, The Neuroimmune Route in ME/CFS, given at Second Annual Community Symposium on the Molecular Basis of ME/CFS, sponsored by Open Medicine Foundation - (Video)
• 14 Mar 2019, Targeted Molecular Diagnosis of ME/CFS – the Devil is in the Details, given at the International Research Symposium, Geelong, Australia, sponsored by Emerge Australia
• 13 Apr 2021, UppTalk Weekly: With hope for the patients with ME, one of the world's most debilitating illnesses.(Conversation in Swedish – subtitles in English) - (Video)

Notable studies

• 2022, Perspective: Drawing on Findings From Critical Illness to Explain Myalgic Encephalomyelitis/Chronic Fatigue Syndrome
• 2021, Lessons From Heat Stroke for Understanding Myalgic Encephalomyelitis/Chronic Fatigue Syndrome
• 2021, Theory: Treatments for Prolonged ICU Patients May Provide New Therapeutic Avenues for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) - (Full text)
• 2021, Hypothesis: Mechanisms That Prevent Recovery in Prolonged ICU Patients Also Underlie Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) - (Full text)
• 2020, Autoantibodies to beta-adrenergic and muscarinic cholinergic receptors in Myalgic Encephalomyelitis (ME) patients – A validation study in plasma and cerebrospinal fluid from two Swedish cohorts - (Full text)
• 2011, Distinct Cerebrospinal Fluid Proteomes Differentiate Post-Treatment Lyme Disease from Chronic Fatigue Syndrome - (Full Text)

See also

• Autoimmune hypothesis
• Open Medicine Foundation
• Sweden

See myalgic encephalomyelitis.

See chronic fatigue syndrome.

cognition Thought processes, including attention, reasoning, and memory.

central nervous system (CNS) - One of the two parts of the human nervous system, the other part being the peripheral nervous system. The central nervous system consists of the brain and spinal cord, while the peripheral nervous system consists of nerves that travel from the central nervous system into the various organs and tissues of the body.

myalgic encephalomyelitis (M.E.) - A disease often marked by neurological symptoms, but fatigue is sometimes a symptom as well. Some diagnostic criteria distinguish it from chronic fatigue syndrome, while other diagnostic criteria consider it to be a synonym for chronic fatigue syndrome. A defining characteristic of ME is post-exertional malaise (PEM), or post-exertional neuroimmune exhaustion (PENE), which is a notable exacerbation of symptoms brought on by small exertions. PEM can last for days or weeks. Symptoms can include cognitive impairments, muscle pain (myalgia), trouble remaining upright (orthostatic intolerance), sleep abnormalities, and gastro-intestinal impairments, among others. An estimated 25% of those suffering from ME are housebound or bedbound. The World Health Organization (WHO) classifies ME as a neurological disease.

autoantibody An antibody that works against the body's own antigens, a hallmark of autoimmune diseases. Autoantibodies are the opposite of an antibodies.

β β / Β. Greek letter beta (a symbol used in science), equivalent to "b".

Involving the neurotransmitter acetylcholine. Cholinergic side effects include diarrhea, blurred vision, decreased intraocular pressure, contricted pupil in the eyes, sweating, increased saliva and mucus on the lungs, bronchial constriction, increased gastrointestinal tone, decreased blood pressure, slow heart rate, and contraction of bladder detrusor muscle. muscle spasms/cramps, low blood pressure, slowed heart rate, nausea and vomiting, increased saliva and sweating, shortness of breath, and urinating more often.

cholinergic Involving the neurotransmitter acetylcholine. Cholinergic side effects include diarrhea, blurred vision, decreased intraocular pressure, contricted pupil in the eyes, sweating, increased saliva and mucus on the lungs, bronchial constriction, increased gastrointestinal tone, decreased blood pressure, slow heart rate, and contraction of bladder detrusor muscle. muscle spasms/cramps, low blood pressure, slowed heart rate, nausea and vomiting, increased saliva and sweating, shortness of breath, and urinating more often.

See National Institutes of Health.

National Institutes of Health (NIH) - A set of biomedical research institutes operated by the U.S. government, under the auspices of the Department of Health and Human Services.